Abeona Therapeutics Inc. (ABEO)
ABEO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/318306/000149315226010413/0001493152-26-010413-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ABEO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000318306 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $5.8M |
| Net income | $71.2M |
| Operating income | -$89.4M |
| Net margin | 1223.1% |
| Operating margin | -1536.9% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $78.4M |
| Total assets | $219.6M |
| P/E (computed) | 2.1× |
| P/S (computed) | 25.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Liquidity In accordance with Accounting Standards Codification ( ASC ) 205-40, Going Concern , the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the accompanying unaudited interim condensed consolidated financial statements were issued." | 10-Q 2026-11-09 |
| Cash and burn | $66.3M cash; operating cash flow -$15.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 57,146,840 (2026-11-05); 54,191,361 a year earlier; 24,773,317 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Morristown, New Jersey, United States | PCAOB Form AP 2026-03-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $3.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $13.5M | -$4.8M | -$8.3M | $66.3M | $11.8M | $39.0M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $11.4M | -$20.2M | -$17.5M | $56.2M | $15.0M | $25.5M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $8.7M | -$17.1M | -$19.8M | $61.4M | $18.1M | $14.5M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $5.4M | -$20.5M | -$18.0M | $78.4M | $20.0M | $5.8M | 10-K 2026-03-17 |
| Q3 2025 2025-09-30 | $0 | -$5.2M | -$21.2M | $82.9M | $19.8M | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $400K | $108.8M | -$18.8M | $163.5M | $19.6M | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$12.0M | -$18.4M | $15.9M | $19.3M | Needs four quarters | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | Not filed | -$9.3M | -$16.6M | $23.4M | $19.0M | Needs four quarters | 10-K 2026-03-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -42.0% |
| 1 month | -46.5% |
| 3 months | -61.9% |
| Year to date | -54.1% |
| 1 year | -46.6% |
| From 52-week high | -67.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VRXA | Veraxa Biotech AG | $1.04 | -5.86% | $147.8M |
| SION | Sionna Therapeutics Inc. | $3.12 | -6.31% | $141.1M |
| ZNTL | Zentalis Pharmaceuticals Inc. | $1.60 | -5.88% | $157.2M |
| BBOT | BridgeBio Oncology Therapeutics Inc. Common Stock | $1.98 | -7.48% | $158.9M |
| RNA | Atrium Therapeutics Inc. | $6.43 | -14.38% | $138.7M |
| MGNX | MacroGenics Inc. | $2.17 | -1.36% | $138.7M |
| ADCT | ADC Therapeutics SA Common Shares | $1.25 | -6.72% | $159.7M |
| MSLE | Satellos Bioscience Inc. | $6.47 | -2.34% | $137.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier